Industry action on antimicrobial resistance assessed in new benchmark

Today at the World Economic Forum’s annual meeting (23–26 January, Davos-Klosters, Switzerland) the Access to Medicine Foundation launched an antimicrobial resistance (AMR) benchmark comparing pharmaceutical companies in their action to tackle growing resistance.

This is the first independent analysis of major pharma players on what they’re doing against AMR. The benchmark compares 30 companies, from big pharma and general producers to biotech companies, on three areas: research and development, manufacturing and production and appropriate access and stewardship, giving each an overall score.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment